Overview

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Southern California
Collaborator:
Celgene Corporation
Treatments:
Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin